RUNX1 and acute myeloid leukemia: Other studies have supported this finding and argue that monitoring MRD using transcript levels of RUNX1/RUNX1T1 fusion gene is favourable over the measurement of other mutations including c-KIT mutations for the risk stratification of AML patients with MRD (75).